HAE Management and Treatment

CE / CME

Expert Guidance on HAE Management and the Evolving Landscape of Prophylaxis

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: March 25, 2025

Expiration: March 24, 2026

Activity

Progress
1 2
Course Completed

References

  1. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77:1961-1990.
  2. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9:132-150 e133.
  3. Guan X, Sheng Y, Liu S, et al. Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review. Orphanet J Rare Dis. 2024;19:256.
  4. UCLA Health. Angioedema. uclahealth.org/medical-services/allergy/disorders-treated/angioedema. Accessed March 5, 2025.
  5. Maas C, Lopez-Lera A. Hereditary angioedema: Insights into inflammation and allergy. Mol Immunol. 2019;112:378-386.
  6. Sylvestre S, Craig T, Ajewole O, et al. Racial and ethnic disparities in the research and care of hereditary angioedema patients in the United States. J Allergy Clin Immunol Pract. 2021;9:4441-4449 e4442.
  7. Grumach AS, Gadir N, Kessel A, et al. Current challenges and future opportunities in patient-focused management of hereditary angioedema: A narrative review. Clin Transl Allergy. 2023;13:e12243.
  8. Henao MP, Kraschnewski JL, Kelbel T, Craig TJ. Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag. 2016;12:701-711.
  9. Radojicic C, Best J, Rosselli J. Despite prophylactic treatments, break-through attacks continue among patients with hereditary angioedema. J Allergy Clin Immunol. 2021:AB21.
  10. Covella B, Giliberti M, Montinaro A, et al. Hereditary angioedema: Novel molecules for treatment of acute attacks and long-term prophylaxis. Future Pharmacology. 2024;4:41-53.
  11. Riedl M. Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism. World Allergy Organ J. 2010;3:S34-38.
  12. Cinryze [prescribing information]. Cambridge, MA: Takeda Pharmaceuticals U.S.A., Inc.; 2024.
  13. Haegarda [prescribing information]. Kankakee, IL: CSL Behring LLC; 2022.
  14. Bernstein JA, Li HH, Craig TJ, et al. Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks. Allergy Asthma Clin Immunol. 2019;15:13.
  15. Lanadelumab-flyo [prescribing information]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc; 2023.
  16. Banerji A, Bernstein JA, Johnston DT, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy. 2022;77:979-990.
  17. Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: A randomized clinical trial. JAMA. 2018;320:2108-2121.
  18. Maurer M, Lumry WR, Li HH, et al. Lanadelumab in patients 2 to less than 12 years old with hereditary angioedema: Results from the phase 3 SPRING study. J Allergy Clin Immunol Pract. 2024;12:201-211 e206.
  19. Berotralstat [prescribing information]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2024.
  20. Zuraw B, Lumry WR, Johnston DT, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021;148:164-172 e169.
  21. Smith TD, Riedl MA. The future of therapeutic options for hereditary angioedema. Ann Allergy Asthma Immunol. 2024;133:380-390.
  22. Tachdjian R, Riedla M, Bordone L, et al. Donidalorsen for hereditary angioedema: results from the OASISplus open-label extension study. Ann Asthma Allergy Immunol. 2024;133:S38.
  23. Riedl MA, Tachdjian R, Lumry WR, et al. Efficacy and safety of donidalorsen for hereditary angioedema. N Engl J Med. 2024;391:21-31.
  24. Craig TJ, Reshef A, Li HH, et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1079-1090.
  25. Reidl M, Anderson J, Arcoleo F, et al. Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary angioedema attacks: Results of CHAPTER-1 phase 2 trial. J Allergy Clin Immunol. 2024;153:AB11.
  26. Cohn DM, Gurugama P, Magerl M, et al. CRISPR-based therapy for hereditary angioedema. N Engl J Med. 2025;392:458-467.
  27. Banerji A, Anderson J, Johnston DT. Optimal management of hereditary angioedema: Shared decision-making. J Asthma Allergy. 2021;14:119-125.